menu search

SNTI / Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates

Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
Senti Biosciences, Inc. (SNTI) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.86 per share a year ago. Read More
Posted: Aug 11 2023, 11:32
Author Name: Zacks Investment Research
Views: 111855

SNTI News  

Senti Bio to Participate in Upcoming Conferences

By GlobeNewsWire
September 26, 2023

Senti Bio to Participate in Upcoming Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company deve more_horizontal

Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 11, 2023

Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates

Senti Biosciences, Inc. (SNTI) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares more_horizontal


Search within

Pages Search Results: